PExA AB (publ) develops and commercializes diagnostic products in various respiratory diseases. It offers its products for asthma, tuberculosis, cystic fibrosis, lung cancer, and chronic obstructive pulmonary diseases. The company’s research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. It offers PExA 2.0, an instrument for the non-invasive collection of particles in exhaled air. The company also provides accessories, which include substrate surfaces and nozzles, as well as parts and service kits. It provides its products for lung research centers within the health services, academia, and pharmaceutical companies. The company was founded in 2004 and is based in Gothenburg, Sweden.
Metrics to compare | PEXAb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPEXAbPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −3.8x | −0.5x | |
PEG Ratio | −0.12 | 0.01 | 0.00 | |
Price/Book | 2.3x | 1.6x | 2.6x | |
Price / LTM Sales | 24.9x | 2.6x | 3.3x | |
Upside (Analyst Target) | - | 59.4% | 42.8% | |
Fair Value Upside | Unlock | 36.2% | 6.5% | Unlock |